Pain Therapeutics, Inc. (PTIE) Sets 12-Month Low at $2.15 on Jun, 29

June 29, 2018 - By Alex Paulin

A yearly low was reached by Pain Therapeutics, Inc. (NASDAQ:PTIE). Today’s price per share was $2.15. It’s 5.00 % below our $2.04. The yearly low was published on Jun, 29 by Barchart.com. The company has $14.83M MC. At $2.04 stock price target, the company valuation changes by $741,250 less.

The stock decreased 4.66% or $0.11 during the last trading session, reaching $2.15.Pain Therapeutics, Inc. has 215,441 shares volume, 82.23% up from normal. PTIE is uptrending and has moved 133.72% since June 29, 2017. PTIE outperformed the S&P500 by 121.15%.

For more Pain Therapeutics, Inc. (NASDAQ:PTIE) news announced briefly go to: Benzinga.com, Benzinga.com, Benzinga.com, Benzinga.com or Schaeffersresearch.com. The titles are as follows: “23 Stocks Moving In Wednesday’s Pre-Market Session” announced on June 27, 2018, “Benzinga’s Daily Biotech Pulse: Epidiolex, Roche’s Influenza Drug Gets Priority Review Status, Xeris Jumps On …” on June 26, 2018, “The Week Ahead: Senate Weighs Sprint-T-Mobile Merger, Nike Earnings And A Slew Of IPOs” with a publish date: June 25, 2018, “Benzinga’s Daily Biotech Pulse: Eli Lilly, Edge Therapeutics, BioXcel Report Positive Trial Results, 4 Stocks Debut” and the last “3 Stocks Sinking in Afternoon Trading” with publication date: June 22, 2018.

Pain Therapeutics, Inc. develops drugs for nervous system disorders in the United States.The firm is valued at $14.83 million. The company's lead drug candidate is REMOXY, a proprietary abuse-deterrent oral formulation of oxycodone to treat severe chronic pain.Currently it has negative earnings. It is also developing FENROCK, a proprietary abuse-deterrent transdermal pain patch for pain relief; PTI-125, a small molecule drug candidate to treat Alzheimer's disease; and PTI-125DX, a blood diagnostic/biomarker to detect Alzheimer's disease.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.